Side-by-side comparison of AI visibility scores, market position, and capabilities
AI drug discovery biotech with $1.7B Takeda deal (Feb 2026). Lead drug IAM1363 (brain-penetrant HER2 inhibitor) in Phase 1. $100M+ raised (2025). Founded 2019, San Diego.
Iambic Therapeutics was founded in 2019 with the mission of applying AI-driven drug discovery to oncology — one of the most complex and high-value areas of pharmaceutical development. The company built proprietary machine learning models for structure-based drug design, training its systems on large datasets of protein-ligand interactions to accelerate hit identification, lead optimization, and candidate selection. This computational-first approach compresses timelines that traditionally require years of iterative chemistry work into months.\n\nIambic's lead asset, IAM1363, is a brain-penetrant HER2 inhibitor targeting HER2-mutated cancers including non-small cell lung cancer and breast cancer with brain metastases — a patient population with limited treatment options and high unmet need. The candidate entered Phase 1 clinical trials as a direct output of Iambic's AI design pipeline, validating the platform's ability to produce clinically viable molecules. The company's AI models are designed to simultaneously optimize for potency, selectivity, and the blood-brain barrier permeability that makes IAM1363 differentiated from approved HER2 inhibitors.\n\nIambic secured a $1.7B collaboration deal with Takeda in February 2026, one of the largest AI drug discovery partnerships in the industry's history, validating both the platform and its pipeline at the highest commercial level. The company raised over $100M in 2025 and has positioned itself alongside Recursion and Insilico Medicine as a leading AI-first biotech with clinical-stage proof points. The Takeda deal provides non-dilutive capital and development resources while preserving Iambic's pipeline optionality across multiple oncology indications.
Indoor vertical farming company using AI-optimized growing systems. San Francisco, CA. Raised $940M+ including $400M from SoftBank. Partners with Walmart for US farms.
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has raised over $940 million from investors including SoftBank Vision Fund, which invested $200 million in 2017, and has positioned itself as the technology leader in data-driven indoor agriculture.\n\nPlenty's farms use precisely controlled light, temperature, humidity, and nutrient conditions to grow crops that are free from pesticides, use 99% less land, and consume significantly less water than conventional field agriculture. The company's AI systems continuously optimize growing conditions based on sensor data, learning to improve yields and quality across crops and growing cycles.\n\nIn 2022, Plenty announced a landmark partnership with Walmart to supply leafy greens from a new large-scale facility in Compton, California. This partnership provided both a major commercial anchor and significant additional funding from Walmart, validating Plenty's technology and business model at scale. The company also operates a dedicated strawberry R&D partnership with Driscoll's, the world's largest berry company, demonstrating the platform's potential beyond leafy greens.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.